Healthcare Equities

The companies that provide, support or coordinate medical goods and services. This sector spans a broad range of activities – including the development and manufacture of medical equipment, pharmaceuticals and other treatments. Activities range from research to manufacturing, administration, insurance and facilities management. Our Healthcare research includes healthcare services, healthcare information technology (IT), medical devices, biotechnology, biopharmaceuticals and specialty pharmaceuticals.

Newron Pharmaceuticals (SIX: NWRN): ENIGMA-TRS2 advances in other countries while US on pause >

Arron Aatkar, PhD | Healthcare | Comment | 1 day ago

Newron Pharmaceuticals (SIX: NWRN): ENIGMA-TRS2 advances in other countries while US on pause >

Arron Aatkar, PhD | Healthcare | Comment | 1 day ago

SEE ALL COMMENTARY >

Actinogen Medical (ACW)

Latest price

AUD0.06

— 0.00 (0.00)

As at 25/09/2026

Market capitalisation: AUD229m

Equities

Equities by Sector

Sectors

Megatrends

Thematics

Latest

Edison explains: The next phase of the obesity market

Edison explains: The cost of insecure infrastructure

Have autos hit the brakes too hard?

Audiovisual

Latest

Webinar – SCHMID Group: Inside the Industry

Freelancer – executive interview

BlackRock Greater Europe Investment Trust – equity proposition

About Edison

Corporates

Investors

Careers

Healthcare Equities

Actinogen Medical (ACW)

AUD0.06

Actinogen Medical — Approaching an inflection point for Xanamem

Actinogen Medical — XanaMIA passes interim analysis and marches on

Actinogen Medical — XanaMIA passes first safety milestone

See morecontent on

AFT Pharmaceuticals (AFT)

NZD4.39

AFT Pharmaceuticals — Making progress on growth strategy

AFT Pharmaceuticals — Setting the stage for sustained long-term growth

AFT Pharmaceuticals — Softer H1 on one-offs; recovery expected in H2

See morecontent on

Allergy Therapeutics (AGY)

GBP0.05

Allergy Therapeutics — H126 results reflect solid progress

See morecontent on

Alzinova (ALZ)

SEK0.42

Webinar: The CNS renaissance Biotech companies at the forefront

Alzinova — Innovative new approach to Alzheimer's

See morecontent on

AOTI (AOTI)

GBP1.30

Argent Biopharma (RGT)

AUD0.03

Argent Biopharma — Valuation report

Argent Biopharma — An innovative approach to drug development

MGC Pharmaceuticals — Rapid prescription growth in Australia and the UK

See morecontent on

Basilea Pharmaceutica (BSLN)

CHF68.70

Basilea Pharmaceutica — Broadening Cresemba’s Japanese opportunity

Basilea Pharmaceutica — Pipeline momentum underpins the next phase

Basilea Pharmaceutica – executive interview

See morecontent on

BioVersys (BIOV)

CHF26.20

BioVersys — Clinical progress, commercial optionality

BioVersys — Fast Track de-risks BV100’s regulatory pathway

BioVersys – executive interview

See morecontent on

Cantargia (CANTA)

SEK1.46

Cantargia — Encouraging data for nadunolimab in CANFOUR

Cantargia — First patient treated in Phase II part of TRIFOUR

Cantargia — Next phase of clinical development in sight

See morecontent on

Cereno Scientific (CRNO-B)

SEK4.12

Cereno Scientific — Successful bridge clears CS014's path to Phase IIb

Cereno Scientific — Active Q226; catalysts move closer

Cereno Scientific – executive interview

See morecontent on

Chosa (CHOSA)

SEK0.60

CHOSA Oncology – executive interview

Outlook for 2024: Life sciences – where has the conviction gone?

Chosa Oncology — Making headway in precision oncology

See morecontent on

Circio Holding (CRNA)

NOK10.16

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on